Metraipolis › archive › dc_a550f7f23ccc
Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine — Europe PMC PMID:40923371
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40923371
- DOI
- 10.1002/cam4.71167
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T05:26:24.024Z
- SHA-256 of the archived text
3ff14c0f5a5c9f4ccae25c83539c69b50778bdb1e3705564166d54e8a1a5c0b1- Stable URL of this page
https://metraipolis.com/documento/dc_a550f7f23ccc
How to cite
Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine — Europe PMC PMID:40923371 — Europe PMC (en), https://europepmc.org/article/MED/40923371 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a550f7f23ccc (Metraipolis archive dc_a550f7f23ccc, sha256 3ff14c0f5a5c9f4ccae25c83539c69b50778bdb1e3705564166d54e8a1a5c0b1)
BibTeX
@misc{dca550f7f23ccc,
title = {Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine — Europe PMC PMID:40923371},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40923371},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a550f7f23ccc; sha256 3ff14c0f5a5c9f4ccae25c83539c69b50778bdb1e3705564166d54e8a1a5c0b1},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40923371. Agents can read the archived copy with the MCP tool read_document.